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Abstract
Classic mechanisms of tumor response to chemother-
apy include apoptosis and mitotic catastrophe. Recent
studies have suggested that cellular senescence, a
terminal proliferationarrest seen in vitro,maybe invoked
during the exposure of cancer cells to chemotherapeutic
agents. To identify markers associated specifically with
the cellular senescence phenotype, we utilized expres-
sion data from cDNA microarray experiments identify-
ing transcripts whose expression levels increased as
human prostate epithelial cells progressed to senes-
cence. When screened against other growth-inhibitory
conditions, including quiescence and apoptosis, many
of these transcripts were also upregulated, indicating
that similar pathways occur between apoptosis and se-
nescence. A senescent-like phenotypewas then induced
in several prostate cancer cell lines using 5-aza-2V-
deoxycytidine, doxorubicin, orDocetaxel. Treatmentwith
these agents resulted in a significant increase in the
induction of senescence-specific genes when com-
pared to nonsenescent conditions. The performance of
the panel was improved with fluorescence-activated
cell sorting using PKH26 to isolate nonproliferating, vi-
able, drug-treated populations, indicating that a hetero-
geneous response occurs with chemotherapy.We have
defined an RNA-based gene panel that characterizes
the senescent phenotype induced in cancer cells by
drug treatment. These data also indicate that a panel of
genes, rather than one marker, needs to be utilized to
identify senescence.
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Introduction
Cellular senescence has been traditionally defined as a
terminal phenotype that is manifest as primary cells un-
dergo prolonged passage in culture [1]. Senescent cells are
terminally arrested, often express senescence-associated
b-galactosidase (SA-b-gal), and assume a characteristic en-
larged, granular, flattened appearance in culture. A similar
phenotype can be achieved in both normal and trans-
formed cells in response to various stimuli including oxida-
tive stress, radiation, activated oncoproteins, and agents that
cause DNA or other cellular damage [2,3]. This terminal growth
arrest is a molecular and cellular phenotype distinct from apop-
totic or catastrophic cell death. The growth arrest that char-
acterizes cellular senescence may be induced by lower doses
of drugs or differentiating agents that result in cytostatic growth
arrest, which persists even following removal of the agent [3].
The onset of senescence in primary cells is mediated by
numerous factors including telomere shortening and altera-
tions in DNA methylation [1]. Discrete changes in genes in-
volved in growth regulation, differentiation, and cell signaling
have been characterized in human prostate epithelial cells
(HPECs) and other cell types during senescence [4–6]. Seve-
ral of these genes, such as the cyclin-dependent kinase (Cdk)
inhibitor p21WAF1/Cip1/Sdi1 and genes downstream from p53,
have been shown to mediate the growth arrest observed at
senescence [7,8]. Other genes, including the Cdk inhibitor
p16INK4a, are involved in the maintenance of senescence [7].
These pathways are frequently targeted for inactivation in the
development of epithelial cancers, including prostate cancer
[9,10]. Studies also suggest that members of the insulin-like
growth factor (IGF) axis, including IGF2 and its IGF-binding
proteins (e.g., IGFBP5), constitute another ‘‘senescence’’ path-
way [4,5]. Reconstitution of senescence-associated genes
in immortal cancer cells by cell fusion, or by selected chromo-
somal or gene transfection leads to reestablishment of the
senescent phenotype, indicating that a finite number of senes-
cence genes and pathways exist [11–15].
In immortalized cells, several stimuli, including DNA dam-
age, oxidative stress, DNA methylation alterations, and histone
deacetylase inhibition, may induce a senescent phenotype
that has been termed ‘‘cellular’’ senescence to distinguish it
from replicative or passage-dependent senescence [16]. Many
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chemotherapeutics function through these and other mech-
anisms, and it has been suggested that the latent senescent
phenotype can be reactivated in cancer cells [3]. Recently, it
was demonstrated that primary murine lymphomas respond
to chemotherapy by engaging an apoptosis or a senescence
program controlled by p53 and p16INK4a [17]. Blocking apop-
tosis by expressing bcl2 results in senescence, indicating
that senescence may represent an alternate mechanism
for cell arrest in some circumstances. These studies have
relied on the identification of senescence-associated-b-
galactosidase (SA-b-gal), an enzyme activity induced during
replicative senescence in primary cells. However, SA-b-gal
can be induced in other stress-associated states, and is ex-
pressed at detectable levels in some proliferating immortal-
ized cancer cells, leading to concern regarding its specificity
as a marker of senescence [18–20]. Therefore, the develop-
ment of a panel of senescence-specific molecular markers
would be useful in the identification of cells displaying the
terminal arrest and morphology associated with senescence.
Strategies to inhibit malignant growth by disabling prolif-
eration, rather than killing cancer cells, have been under-
studied and represent an area of intense interest. In this
manuscript, we identify and confirm a series of molecular
markers that distinguish senescence in primary and tumor
cells of epithelial origin. These markers are upregulated in
senescence, in contrast to apoptosis and quiescence. We
find that these markers are induced after the treatment of
prostate cancer cells in vitro with chemotherapeutics that in-
duce a senescent phenotype. Reexpression of two of these
markers,CXCL14/BRAK and P311, has been found to inhibit
cellular and tumor growth [21,22]. These data indicate that
a subset of genes upregulated during senescence in pri-
mary cells are also induced in cancer cells undergoing cel-
lular senescence. Given that drug-induced senescence may
occur with chemotherapy, these markers may assist in iden-
tifying and exploiting the senescent phenotype in human
cancer treatment.
Materials and Methods
Cell Culture and Drug Treatment
Primary HPECs were established and maintained as
described previously [7]. HPECs were forced to undergo
quiescence by contact inhibition for 96 hours in serum-
depleted media. HPECs were treated with staurosporine and
thapsigargin from 4 to 48 hours to induce apoptosis. The
selected concentration to maximize apoptosis was 1 mg/ml
staurosporine and 1 mM thapsigargin. The degree of apop-
tosis was determined through quantitation of fragmented
nuclei—a hallmark of the apoptotic process. Cells were fixed
for 30 minutes on ice in 1% phosphate-buffered saline
(PBS)-buffered paraformaldehyde. Cells were washed in
PBS and resuspended in PBS containing 0.1% NP-40 and
1 mg/ml Hoechst 33342. Fragmented nuclei were visual-
ized by fluorescence microscopy. The percent fragmented
nuclei compared to intact nuclei was determined in three
independent experiments.
The prostate cancer cell lines, DU145 and LNCaP,
were plated the day before the drug treatment so that they
would be 50% confluent on the day of treatment. The topo-
isomerase II inhibitor, doxorubicin (Sigma, St. Louis, MO),
or microtubule-stabilizing agent, Docetaxel (Aventis Phar-
maceuticals Products Inc., Bridgewater, NJ), was added to
the cells at days 1 and 3. Regular growth medium DMEM
with 5% FBS was then resumed from days 4 to 7 when the
cells were harvested for downstream analyses. 5-Aza-2V-
deoxycytidine (DAC; Sigma), a methyltransferase inhibitor,
dosed continuously for 7 days before harvest. A series
of dose-ranging studies was performed, as previously de-
scribed [15]: 5 to 200 nM for doxorubicin, 0.1 to 10 nM for
Docetaxel, and 0.25 to 250 mM for DAC. The final drug doses
were chosen based on induction of the senescence pheno-
type as assessed by phenotype and fluorescence-activated
cell sorting (FACS) analysis 7 days after initial drug treat-
ment. All cells were incubated at 37jC with 5% CO2 during
the drug treatment. SA-b-gal staining was performed as pre-
viously described and five random high-power fields were
counted for staining in each culture [23].
Quantitative Reverse Transcriptase Polymerase
Chain Reaction (RT-PCR) Gene Quantitation
Total RNA was isolated from drug-treated cells using
the RNeasy RNA isolation kit (Qiagen). On column DNase
treatment was used to eliminate DNA contamination. One
microgram of total RNA was used to make cDNA. Quantita-
tive PCR was performed by monitoring in real time the
increase in fluorescence of the SYBR Green dye using an
iCycler detection system (Bio-Rad) as described [4]. For
comparison of transcript levels between samples, a stan-
dard curve of cycle thresholds for several serial dilutions
of a cDNA sample was established. This value was then
used to calculate the relative abundance of each gene.
These values were then normalized to the relative amounts
of 18S cDNA. All PCR reactions were performed in dupli-
cate. Sequences of primers used for PCR analysis are avail-
able on request. We compared the proportion of the nine
genes that were observed to have at least a two-fold
increase between the senescent conditions and the non-
senescent conditions using an unpaired t-test. Prior to test-
ing, the proportions were transformed using an arcsine
square-root transformation in order to better meet the as-
sumptions of the analysis. A P-value less than .05 was
considered significant.
Cell Cycle Analysis, Viability, and Apoptosis
Cells were trypsinized in 0.05% trypsin, 0.53 mM EDTA–
4Na in Hank’s Balanced Salt Solution (Cellgro) and re-
suspended in growth media with 10 mg/ml of propidium iodide
(Sigma) and analyzed for cell viability by flow cytometry.
Another aliquot of the cells that were harvested at the same
time point was washed with cold 1 PBS followed by fixation
in 90% ethanol overnight at 20jC. Cells were centrifuged,
resuspended in PBS, then 0.5% NP-40 solution was applied
to the cells with RNase A to a final concentration of 250 mg/ml.
Propidium iodide stock solution was added to the cells to
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10 mg/ml and incubated at 37jC for 5 min. The stained cells
were analyzed for DNA content and cell cycle distribution.
Data was acquired on a FACScan benchtop flow cytometer
(Becton Dickinson, San Jose, CA). Ten thousand events
were acquired with CellQuest software (Becton Dickinson).
Cell cycle position was determined with MODFiT LT (Verity,
Topsham, Maine).
For PKH26 analysis of cell division, 1  107 cells were
trypsinized and stained with PKH26-GL (Sigma) accord-
ing to manufacturer’s protocol. Cells were replated, treated
with the individual drugs and PKH26 fluorescence was exam-
ined seven days after initial treatment by FACS analysis. Cells
with high fluorescence represent nondividing cells whereas
cells with low fluorescence represent cells that have under-
gone cell divisions. FlowJo software (Tree Star, Inc.) was used
to distinguish the proliferating and growth arrest cell popu-
lations. Total RNA was isolated from half of the sorted cells
and the remainder were plated and stained for SA-b-gal.
Results
Identification of Genes with Increased mRNA Expression
in Senescent Cells
To identify genes specifically upregulated with cellular
senescence, we initially focused on genes induced in HPECs
when passaged to senescence in vitro. Previously, we had
generated gene expression profiles from primary prostate
epithelial cells and identified 93 independent image clones
consisting of known genes, ESTs, and hypothetical proteins
that were significantly induced in senescence [24]. To con-
firm gene induction, three independent primary HPECs
cultures were grown to senescence, RNA isolated and
converted to cDNA. Real-time quantitative RT-PCR (QPCR)
was performed to monitor gene expression by compar-
ing proliferating and senescent samples. The induction of
46 genes was confirmed, of which 42 were characterized
and 4 were hypothetical proteins (Supplemental Table 1).
Subsequent analyses were performed on robustly induced
genes (change of greater than four-fold), refining the group
to 17 genes (Table 1).
Identification of Senescence-Specific Genes
Other cell cycle arrest and stress states may share gene
expression changes in common with senescence. To define
a senescence-specific gene panel, we initiated growth arrest
and apoptosis by several means. First, growth arrest was
achieved by propagating HPECs and fibroblasts to conflu-
ence. Cells were then maintained in a 100% confluent and
arrested state for 4 days in serum-depleted media. HPECs
did not stain for SA-b-gal at confluence, in contrast to fibro-
blasts, which were positive as previously documented [25].
Arrested cells were harvested, and the 17 genes robustly in-
duced at senescence (above) were analyzed by QPCR. This
experiment revealed that FBXO32, PLXDC2, AK024270,
OLFML2A, andWnt5awere also induced at confluence arrest
(Table 2). These five genes did not undergo further analysis.
Shared signaling pathways exist between senescence
and apoptosis (i.e., p53-related) [1], yet we hypothesized
that specific genes are induced with senescence. We in-
duced apoptosis using two non–DNA-damaging drugs, stau-
rosporine and thapsigargin. Staurosporine is a known kinase
inhibitor [26], whereas thapsigargin induces apoptosis by di-
recting an intracellular calcium flux [27]. DNA-damaging agents
have been documented to induce a senescent phenotype
and were avoided [3]. HPECs were treated with 1 mg/ml
staurosporine or 1 mM thapsigargin for up to 48 hours, and
nuclei were visualized under fluorescent microscopy after
Table 1. Gene Expression in HPEC Senescence.
Gene Accession Number Fold Change
CSPG2 NM_004385 25
PLXDC2 AY358486 21
EST BG391777 19
Wnt5a NM_003392 18
DOC1 NM_182909 17
FBOX32 AK125888 12
OLFML2A BC054001 12
IGF2 AK074614 11
Adlican AF245505 10
COL1A1 Z74615 9.0
MMP2 AL832088 8.6
RKHD3 AK131424 8.4
CKTSF1B1 AF110137 5.5
MFAP2 BC028033 5.2
CXCL14 NM_004887 4.6
P311 BC011050 4.6
MDK BM473044 4.1
The expression of 93 genes previously identified to be induced in HPEC
senescence by microarray [4] were assayed by QPCR in three additional
HPEC cultures undergoing senescence.
Those genes induced greater than four-fold are shown above.
Gene expression was standardized to 18S rRNA expression, and the ratio
of expression in senescent cells to the expression in proliferating cultures
was determined.
Table 2. The Effect of Apoptosis and Confluence Arrest on Genes Induced
in HPEC Senescence.
Gene Confluence
Arrest
Staurosporine
(1 mg/ml)
Thapsigargin
(1 mM)
HPEC Fibroblast 4 hr 12 hr 48 hr 24 hr 48 hr
CSPG2 1.1 1.0 1.0 1.1 1.0 0.5 0.2
PLXDC2 1.1 2.3 0.8 1.9 2.5 1.1 3.1
EST (BG39177) 0.6 0.8 1.1 0.8 0.5 1.6 4.3
Wnt5a 1.2 3.9 1.1 0.4 0.2 1.4 17.2
DOC1 0.8 1.5 1.2 0.1 0.2 0.5 0.4
FBOX32 0.9 5.1 1.1 0.6 1.1 2.4 4.6
OLFML2A 1.0 23.0 1.0 0.8 1.1 0.6 0.6
IGF2 0.8 0.8 1.0 1.4 2.4 0.6 0.3
Adlican 1.5 0.8 1.0 0.7 1.2 1.0 0.9
COL1A1 0.5 0.6 1.2 0.5 0.4 0.6 0.9
MMP2 0.8 1.4 1.0 1.2 1.1 0.5 0.7
RKHD3 0.8 0.9 1.0 1.1 2.0 0.8 1.1
CKTSF1B1 1.1 1.0 1.0 1.8 13.0 1.5 0.9
MFAP2 0.8 1.0 0.9 0.3 0.2 1.7 0.4
CXCL14 1.9 1.0 0.9 0.9 0.9 0.2 0.3
P311 0.9 1.0 0.9 0.6 0.6 0.3 0.5
MDK 1.1 1.8 1.0 2.6 3.9 1.2 1.0
Cells were induced to undergo growth arrest in response to confluence, or
apoptosis by drug treatment.
The relative ratio of gene expression, determined by QPCR, on drug
treatment/confluence to that of the untreated cells is listed.
Highlighted genes did not increase expression under these conditions.
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Hoechst 33342 staining for fragmentation and condensa-
tion. Both drugs effectively lead to reduced viability and
initiated apoptosis (Figure 1). Gene expression analysis
from cells treated with apoptosis-inducing drugs revealed
that CKTSF1B1, PLXDC2, MDK, and IGF2 were induced by
greater than two-fold with staurosporine treatment (Table 2).
BC071787, FBOX32, PLXDC2, and Wnt5a were induced
with thapsigargin treatment. Eight of 17 genes induced with
senescence at high levels were also induced with apop-
tosis. The remaining genes define a nine-gene ‘‘senescence-
specific’’ panel that is induced in senescent epithelial cells,
but not with growth arrest or apoptosis (Table 2).
Cellular Senescence Induction in Prostate Cancer Cells
This senescence panel was then applied to several
models of drug-induced cellular senescence using prostate
cancer cell lines. Analyses were performed on whole cultures
and sorted populations. We used chemical agents previously
reported to induce a senescent-like phenotype including DAC,
a methyltransferase inhibitor [28], and doxorubicin, which acts
primarily to inhibit the topoisomerase II complex [29]. In ad-
dition, Docetaxel, a microtubule-stabilizing agent active in
prostate cancer, was tested [30]. Dose-ranging studies were
performed and cells were assessed at day 7 after initial drug
exposure. By this time point, initial cell death processes had
been completed and the viable senescent phenotype, as de-
fined below and by trypan blue exclusion staining, becomes
predominant at selected doses.
Senescence was determined through the use of sev-
eral criteria. The first was the development of a flattened,
enlarged morphology (Figure 2A). Second, flow analysis
was used to confirm this increase in size and cellular com-
plexity by documenting an increase in side scatter (SSC).
Third, growth arrest was recognized by a proliferative failure
of treated cultures. Finally, polyploidy, indicating multinuc-
leation, a feature of senescent cells [31,32], was evident
in treated cells (Figure 2B). Drug concentrations were opti-
mized for DAC, doxorubicin, and Docetaxel to reproducibly
induce a senescent-like phenotype in DU145 and LNCaP cells
(Table 3). DU145 cells treated with Docetaxel did not induce
a senescent phenotype based on these criteria at any dose.
To further refine the senescent population in these drug-
treated cultures, DU145- and LNCaP-treated cells were
stained prior to treatment with PKH26, a lipophilic fluorescent
compound that incorporates into the plasma membrane.
PKH26 fluorescence decreases with each cell division. With
the exception of Docetaxel-treated DU145 cells, all drug
doses at day 7 demonstrated a significant increase (over
50%) in the high-fluorescence fraction compared to control
cultures (Figure 2C). A defined single peak was also found,
indicating that the majority of cells had decreased prolif-
eration. A comparison of SA-b-gal staining of high-fraction
fluorescence cells revealed significant increases (three-fold
to five-fold) in staining for drug-treated DU145 cells com-
pared to control (data not shown). LNCaP cells were unable
to be replated after sorting and were not analyzed for SA-
b-gal. These data demonstrate that drug-treated cultures
were generated with the phenotypic and cell cycle char-
acteristics of induced cellular senescence.
Induction of the ‘‘Senescence Panel’’ during Drug-Induced
Cellular Senescence
The nine-gene senescence panel was then assessed
using QPCR in the whole (Table 4) and PKH26-sorted
cultures after drug treatment. Analysis of the expression of
the nine genes in five unsorted senescent cultures (45 data
points) resulted in the more than two-fold induction of the
senescence markers in 30 cases. CSPG2 and CXCL14
expression was consistently increased in senescence, over
20-fold in doxorubicin-treated cells, when compared to un-
treated cells. Adlican, COL1A1, DOC1,MFAP2, and RKHD3
were upregulated in the majority (60–80%) of senescent
conditions. Both DAC and doxorubicin were equally profi-
cient in inducing the nine-gene senescent gene panel. A
comparison of gene expression under conditions that did
not induce the senescent criteria to those that did (Table 3)
revealed that only two (22%) of the nine genes showed at
least a two-fold increase under the nonsenescent condi-
tions, in contrast to six (67%) under senescent conditions
(P = .0008). Thus, a panel of genes specifically upregulated
in primary cell senescence is also found to be significantly
increased with induced cellular senescence in immortalized
cancer cells.
For PKH26-stained cells, the high-staining (i.e., growth-
inhibited) fraction was compared to proliferating, FACS-
sorted control cultures. A greater than two-fold increase in
Figure 1. HPEC apoptotic induction. HPECs were treated with 1 g/ml
staurosporine (A) or 1 M thapsigargin (B). At the indicated time points, cells
were trypan blue–stained for viability and fragmented nuclei were detected
with Hoechst 33342 and fluorescent microscopy. The percentages of viable
and apoptotic cells are shown ± SD.
Identification of Senescence-Specific Genes Schwarze et al. 819
Neoplasia . Vol. 7, No. 9, 2005
expression was seen in 35 of 45 genes (five sorted cultures),
and 31 of these increases were over four-fold. All markers
were increased in DAC- and doxorubicin-treated DU145
cells. This demonstrates that enrichment of the viable,
growth-arrested population improves the precision of the
senescence panel.
Discussion
Chemotherapy induces a senescence-like terminal prolifer-
ation arrest that is distinct from apoptosis and mitotic catas-
trophe [3]. SA-b-gal staining has been utilized to putatively
identify this phenotype in aging human tissues and human
cancers; however, this marker lacks specificity [19,20]. In
contrast to apoptosis, confirmatory markers have not been
developed for senescent human cells. We previously iden-
tified a number of genes whose expression was increased
or decreased in normal prostate epithelial cells when devel-
oping a senescent phenotype after limited passage in cul-
ture [4]. In the current manuscript, we identified a subset of
genes that are highly upregulated at senescence in pros-
tate epithelial cells, and screened these genes against cells
undergoing apoptosis or confluence arrest. Our initial find-
ing is that many genes were found to demonstrate increased
expression in both apoptosis and senescence, consistent
with pathways in common between these two processes.
Figure 2. Treatment of prostate cancer cell lines with senescence-inducing drugs. (A) DU145 treated with doxorubicin (25 nM) after 7 days reveals that cancer cells
are growth-arrested and have a viable phenotype consistent with senescence. Untreated cells (left, 400) show the standard cuboidal morphology. In contrast,
doxorubicin-treated cells (right, 400) are greatly enlarged, flattened, and contain well-defined, occasionally multiple nuclei. (B) FACS analysis of DNA content
distribution of a typical exponentially growing control cell population is composed of two peaks (G1/G0 and G2/M phase) and a valley of S phase. Little change is
seen in DU145 cells treated with 5 nM doxorubicin. A significant shift toward a higher FL2 area and additional peaks (higher DNA content area) are seen in
senescent cultures (25 nM), indicating the development of polyploid nuclei, a feature of senescent cells. (C) FACS analysis of cell division after PKH26 staining of
drug-treated (Table 3) and untreated LNCaP prostate cancer cells. Cells with high fluorescence represent nondividing cells (right shift) and cells with low
fluorescence represent cells that have undergone cell divisions. The population of cells with increased fluorescence after drug treatment (decreased cell pro-
liferation) was analyzed for senescent panel gene expression.
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However, senescence-specific genes were identified. We
applied this panel to a series of cancer cells that had a se-
nescent phenotype induced using various chemotherapeutic
agents, and find consistent increases in expression in these
models. During immortalization, genes in senescence path-
ways may be inactivated, either through genetic or epi-
genetic means, and bypassing senescence requires each
of these pathways to be altered [11]. The reexpression of the
majority, but not all, of our gene markers suggests that re-
activation of one or more of these pathways occurs with es-
tablishment of the senescent phenotype in cancer cells. This
indicates the need for utilizing a panel of genes, rather than
one gene, to evaluate for senescence.
Chemotherapy type and dose, as well as genetic context,
are variables that contribute to determining whether a cell be-
comes apoptotic or senescent [3]. We optimized a series of
drugs with different therapeutic mechanisms to induce a se-
nescent phenotype. Senescence is a differentiated phenotype
that is defined in primary cells based on morphology, viability,
cell cycle arrest, aneuploidy, and the expression of SA-b-gal
[1,31,33]. Similar criteria were utilized for treated cancer cells.
We find that 8 of 17 genes induced at senescence were also
increased with apoptosis, suggesting common pathways be-
tween the two processes. None of these genes is known to be
directly regulated by p53, an important gene in signaling both
these events [34]. Importantly, genes specifically upregulated
in senescence were identified, confirming that distinct senes-
cence pathways exist [11]. Chemotherapeutic drugs that did
not induce a senescent phenotype in certain cell types despite
variations in dosing and schedule (i.e., DU145 with Docetaxel)
were encountered. Recently, it was demonstrated that primary
murine lymphomas respond to chemotherapy by engaging an
apoptosis or a senescence program controlled by p53 and
p16INK4a [17]. Blocking apoptosis by expressing bcl2 results
in senescence, indicating that similar signaling pathways may
trigger these phenotypes, but the fate of a cancer cell is de-
pendent on the genetic context.
The majority of genes in the senescence-specific panel
were induced with onset of the senescent phenotype in the
cancer cell lines studied. Our data show that CSPG2 and
CXCL14 mRNA upregulations are highly and consistently
associated with prostate cells that have undergone senes-
cence through either passage or chemotherapeutic treatment
regimens. These genes are also upregulated with human
fibroblasts grown to senescence (data not shown). The other
genes induced in our senescence-specific panel (DOC1,
MFAP2, Adlican, COL1A1, MMP2, and P311) demonstrate
more of a dependence on the drug and cell types examined
in unsorted cultures. However, these genes were uniformly
upregulated by enriching the treated cells for the viable,
low-proliferation senescent fraction (high PKH26). These find-
ings indicate that the senescence response to chemotherapy
is heterogeneous even with an optimization of dose and
timing. Although CSPG2 and CXCL14 appear to be the most
reliable senescence-specific molecular markers in this model,
we would advocate using multiple markers because senes-
cence genes and pathways are often deleted or mutated.
The genes identified in the senescence panel represent
diverse biologic functions. Putative structural roles have been
assigned to DOC1 (deleted in ovarian cancer) and MFAP2,
a microfibril-associated glycoprotein [35,36]. Alterations in
these genes may reflect the enlarged, flattened morphology
that characterizes senescence. Others are secreted (e.g.,
Adlican,COL1A1,CSPG2,CXCL14, andMMP2).Adlican has
been found to be overexpressed in skin fibroblasts from
centurians, but its function is unknown [37]. A debate exists
whether senescent cells may provide an environment that
stimulates or inhibits tumor growth [38]. Several secreted
Table 3. Induction of Senescence Characteristics in DU145, PPC-1, and
LNCaP Cells after Chemotherapy Treatment for 7 Days.
Cell Line Drug Dose Viability
(%)
Complexity
Change*,y
(%)
Ploidy
Change*
(%)
Apoptosisz
(%)
DU145 Control – 95 – – 0.3
DAC 0.4 MM 57 66 129 2.0
Docetaxel 1 nM§ 87 32 100 0.3
Doxorubicin 5 nM§ 94 29 35 0
25 nM 85 65 335 0.9
LNCaP Control – 79 – – 2
DAC 75 MM 51 63 60 0.8
Docetaxel 5 nM 48 83 20 0.5
Doxorubicin 5 nM§ 83 6 10 0.8
25 nM 65 22 120 0.9
Cells were harvested and analyzed by flow cytometry for viability, complexity
(SSC), ploidy, and apoptosis.
*Represents percentage change from untreated cells.
yComplexity refers to SSC.
zApoptosis is the absolute percentage calculated from flow analysis and
confirmed by Annexin V staining.
§Selected drug concentrations and doses that did not induce senescence are
also shown.
Table 4. Expression of the Senescence-Specific Gene Panel Following Chemotherapy Treatment in Unsorted Prostate Cancer Cell Lines.
Drug Cell Lines Dose CSPG2 DOC1 Adlican MFAP2 P311 CXCL14 COL1A1 RKHD3 MMP2
DAC DU145 0.375 MM o . o
LNCaP 75 MM o o o o
Docetaxel LNCaP 5 nM . o o o
Doxorubicin DU145 25 nM . o . o . o
LNCaP 25 nM . o o o
DU145 or LNCaP cells treated with the DAC, Docetaxel, or doxorubicin for 1 week were analyzed for mRNA expression of the genes listed below using QPCR.
(o) No change or decrease;
( ) increased two-fold to four-fold;
( ) increased four-fold to eight-fold;
(.) increased more than eight-fold.
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genes, MMP2 and CSPG2, are proteases found to have in-
creased levels in the peritumor extracellular matrix of cancers,
suggesting a role in promoting tumor invasion [39,40]. Alter-
nately, senescence genes may impede cancer progression.
The overexpression of the chemokine CXCL14 inhibits the
growth of LAPC4 prostate cancer xenografts [21] and pre-
vents angiogenesis [41]. The expression of P311, a gene
involved in smooth muscle myogenesis, leads to neuron dif-
ferentiation and the induction of p21 expression, a gene im-
portant in signaling senescence [22]. The diverse biologic
functions of these genes should, with further study, lend in-
sights into common pathways involved in modulating senes-
cence in cancer cells.
This study identifies and confirms a molecular definition of
senescence, based on mRNA expression, in human cancer
cells after treatment with chemotherapy. Senescence is a
distinct form of cell arrest activated with cancer therapy,
including chemotherapy and possibly radiation. Even though
senescent tumor cells are not destroyed but arrested, this
may be a feasible approach to controlling cancer. However,
some genes upregulated at senescence may have protu-
morigenic effects so the definitive effects of this phenotype
remain to be determined [38]. Studies have detected SA-b-
gal expression in human and mouse tumors after chemo-
therapy, suggesting that senescence occurs in vivo [17,42].
The current study defines a series of genes useful in iden-
tifying senescent cells, and further analyses will confirm
their application to senescence in vivo.
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